Adicet Bio Advances with FDA Clearance and Upcoming Trial

Adicet Bio (ACET) has shared an announcement.

Adicet Bio, Inc. has received FDA clearance for its Investigational New Drug application for ADI-270, aimed at treating relapsed/refractory renal cell carcinoma. The company is set to begin a Phase 1 trial in the latter half of 2024 to evaluate the safety and effectiveness of the therapy, with preliminary results expected in the first half of 2025. ADI-270 is an innovative “off-the-shelf” CAR T cell therapy, and the upcoming trial will explore its potential as a monotherapy for adults with this challenging form of cancer.

For an in-depth examination of ACET stock, go to TipRanks’ Stock Analysis page.